This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
 
 Features and benefits
 * Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years
 * Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
 Highlights
 Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
 
 Your key questions answered
 * Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector
 * Determine the value of BMS's piepline and other strategies the company is taking to counteract an imminent wave of generic compeitition.
 * Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger.